Filter Results:
(602)
Show Results For
- All HBS Web
(602)
- People (1)
- News (203)
- Research (300)
- Events (3)
- Multimedia (10)
- Faculty Publications (172)
Show Results For
- All HBS Web
(602)
- People (1)
- News (203)
- Research (300)
- Events (3)
- Multimedia (10)
- Faculty Publications (172)
- October 2016 (Revised November 2016)
- Case
Innovating Beyond Ochsner
By: Richard G. Hamermesh and Olivia Hull
The Ochsner Health System has developed a proprietary software tool designed to treat hypertension. Built into the system’s electronic medical records, the Hypertension Digital Medicine program allows patients to record their blood pressure at home and share readings... View Details
Keywords: Electronic Medical Records; Telemedicine; Hypertension; High Blood Pressure; Chronic Disease; Entrepreneurship; Health Disorders; Business Model; Business Startups; Innovation and Invention; Growth Management; Marketing Strategy; Product Launch; Product Positioning; Science-Based Business; Business Strategy; Health Industry; Technology Industry; New Orleans; Louisiana
Hamermesh, Richard G., and Olivia Hull. "Innovating Beyond Ochsner." Harvard Business School Case 817-028, October 2016. (Revised November 2016.)
- October 2012
- Teaching Note
Angola and the Resource Curse (TN)
By: Aldo Musacchio, Eric Werker and Ian Cornell
- September 2014 (Revised May 2017)
- Case
Fresno's Social Impact Bond for Asthma
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Social Impact Bonds (SIBs) were quickly gaining popularity as an investment vehicle which joined together private investors and nonprofits to tackle social issues. Although numerous SIB projects and proposals had cropped up across the U.S. following the launch... View Details
Keywords: Social Enterprise; Health Care; Marketing; Bonds; Financing; Asthma; Air Pollution; Air Quality; Chronic Disease; Public Health; Health; Health Care and Treatment; Finance; Health Industry; Financial Services Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "Fresno's Social Impact Bond for Asthma." Harvard Business School Case 515-028, September 2014. (Revised May 2017.)
- May 2021
- Case
Colombia: An Economic Premium to Peace?
Colombia, once the fastest growing country in Latin America, continues to struggle with productivity. Both labor productivity and total factor productivity have been low for the past decade, despite economic growth of 4.7% annually. Many factors contribute, which... View Details
Keywords: Productivity; Productivity Growth; Conflict; Labor Force Participation; Labor Market; Competitiveness; Dutch Disease; Security; Peace; Informality; Labor Laws; Total Factor Productivity; Labor Productivity; COVID-19 Pandemic; Economics; Development Economics; Economic Growth; Economy; Macroeconomics; Conflict Management; Competitive Advantage; Infrastructure; Negotiation; Inflation and Deflation; Non-Renewable Energy; National Security; Government Administration; Latin America; Central America; Colombia; South America
Vietor, Richard H.K. "Colombia: An Economic Premium to Peace?" Harvard Business School Case 721-053, May 2021.
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details
Keywords: Drug Development; Drug Discovery; Drug Trials; Pharmaceutical Companies; Pharmaceutical Company; Pharmaceuticals; Therapeutics; Biologics; Biotech; Biotechnology; Biopharmacy Company; Biochemistry; Technology Commercialization; Technology Companies; Drug Testing; Startup; Start-up; Startups; Start-ups; Startup Financing; Strategic Decision Making; Strategic Decisions; Strategic Evolution; FDA; Food And Drug Administration; Clinical Trials; Disease Management; Market Attractiveness; Market Entry; Market Opportunities; Health Disorders; Technological Innovation; Information Technology; Commercialization; Business Startups; Finance; Decision Making; Strategy; Market Entry and Exit; Opportunities; Pharmaceutical Industry; Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.
- January 2017
- Case
Danaher Corporation, 2007–2017
By: John R. Wells and Gabriel Ellsworth
On July 2, 2016, Danaher Corporation completed the spinoff of Fortive Corporation. The previous day, Danaher’s stock price had reached an all-time high. In 2015, Danaher had decided to split off its test and measurement, fuel and fleet management, and automation... View Details
Keywords: Danaher; Fortive; Larry Culp; Beckman Coulter; Pall; Life Sciences; Diagnostics; Environmental Operations; Water Management; Dental; Testing; Measurement; Fuel; Fleet Management; Automation; Toolmaking; Tools; Disease Management; Continuous Improvement; Toyota Production System; Divestiture; Spinoffs; Spin-off; Networks; Acquisition; Mergers and Acquisitions; Business Conglomerates; Business Divisions; Business Subsidiaries; Business Units; Business Growth and Maturation; Business Model; For-Profit Firms; Joint Ventures; Restructuring; Engineering; Chemicals; Construction; Machinery and Machining; Profit; Revenue; Globalized Firms and Management; Multinational Firms and Management; Health; Health Care and Treatment; Health Disorders; Medical Specialties; Business History; Job Cuts and Outsourcing; Business or Company Management; Growth and Development Strategy; Management Analysis, Tools, and Techniques; Management Practices and Processes; Management Succession; Management Systems; Resource Allocation; Market Entry and Exit; Measurement and Metrics; Logistics; Business Processes; Organizational Change and Adaptation; Public Ownership; Problems and Challenges; Science; Genetics; Natural Environment; Wastes and Waste Processing; Science-Based Business; Opportunities; Strategy; Adaptation; Business Strategy; Competition; Competitive Strategy; Competitive Advantage; Consolidation; Corporate Strategy; Diversification; Expansion; Technology; Software; Technology Networks; Technology Platform; Value; Valuation; Aerospace Industry; Auto Industry; Biotechnology Industry; Chemical Industry; Computer Industry; Construction Industry; Consumer Products Industry; Distribution Industry; Electronics Industry; Food and Beverage Industry; Health Industry; Industrial Products Industry; Information Technology Industry; Manufacturing Industry; Medical Devices and Supplies Industry; Pharmaceutical Industry; Retail Industry; Rubber Industry; Semiconductor Industry; Shipping Industry; Technology Industry; Telecommunications Industry; Utilities Industry; United States; District of Columbia
Wells, John R., and Gabriel Ellsworth. "Danaher Corporation, 2007–2017." Harvard Business School Case 717-464, January 2017.
- 15 Jun 2020
- Research & Ideas
A Mass Crisis Can Overwhelm Health Care. Liberia Found a Solution.
quickly and efficiently for COVID-19 in the US, he says. The training modules cover four areas including epidemic surveillance; maternal and child health care; identifying Malaria, tuberculosis, and HIV; and referrals and chronic disease... View Details
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- January 2023 (Revised September 2024)
- Supplement
The END Fund (B)
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details
Keywords: Health Disorders; Investment Funds; Global Range; Nonprofit Organizations; Resource Allocation; Decisions; Health Care and Treatment; Mission and Purpose
Rangan, V. Kasturi, and Courtney Han. "The END Fund (B)." Harvard Business School Supplement 523-064, January 2023. (Revised September 2024.)
- 24 Oct 2014
- News
Ebola as a Wake-Up Call
- January – February 2008
- Article
The Dangers of Wishful Thinking
By: Richard S. Tedlow and David Ruben
Too many U.S. businesses (including tires, super-markets, and information technology) have been infected with the disease of denial. The answer? In Lincoln's words, “We must disenthrall ourselves.” View Details
Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Leadership; Growth and Development Strategy; Success; Behavior; Cognition and Thinking
Tedlow, Richard S., and David Ruben. "The Dangers of Wishful Thinking." The American: A Magazine of Ideas (January–February 2008).
- 22 Sep 2020
- Working Paper Summaries
Older People Are Less Pessimistic about the Health Risks of COVID-19
- October 2003 (Revised February 2010)
- Case
The Duke Heart Failure Program
By: Richard M.J. Bohmer and Laura Feldman
Duke University Health System has for the past five years operated a specialized clinic for the management of congestive heart failure, a very common and costly condition in the surrounding community. Nurse practitioners, whose work is guided by highly specified... View Details
Keywords: Health Care and Treatment; Health Disorders; Medical Specialties; Time Management; Service Delivery; Service Operations; Outcome or Result; Health Industry
Bohmer, Richard M.J., and Laura Feldman. "The Duke Heart Failure Program." Harvard Business School Case 604-033, October 2003. (Revised February 2010.)
- April 2003
- Module Note
Design and Management of Health Care Delivery Processes, The
By: Richard M.J. Bohmer
Discusses the design and management of clinical processes in health care. Presents a framing of the clinical process as a problem-solving process that fundamentally involves learning along two dimensions and at least two levels. The two dimensions are: 1) learning in... View Details
Keywords: Management Analysis, Tools, and Techniques; Service Delivery; Management Practices and Processes; Learning; Health Care and Treatment; Health Industry
Bohmer, Richard M.J. "Design and Management of Health Care Delivery Processes, The." Harvard Business School Module Note 603-107, April 2003.
- 04 Oct 2018
- News
Precision medicine needs a business mindset in order to flourish
- 28 Sep 2020
- Working Paper Summaries
What Can Economics Say About Alzheimer's Disease?
- 21 Nov 2005
- Research & Ideas
The Geography of Corporate Giving
Why companies support nonprofits and other socially responsible activities is an intriguing question for both academics and practitioners. After all, there is no clear-cut evidence that corporate "do-gooding" results in greater returns for shareholders. In an... View Details
Keywords: by Sean Silverthorne
- 16 Aug 2012
- News
Switzerland Has Its Own Kind of Obamacare — and Loves It
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.